212,427 Shares in PROCEPT BioRobotics Corporation $PRCT Purchased by Mitsubishi UFJ Asset Management Co. Ltd.

Key Points

• Mitsubishi UFJ Asset Management bought 212,427 PROCEPT BioRobotics shares worth approximately $4.8 million, giving it a 0.37% stake. Institutional investors and hedge funds collectively own 89.46% of the company.
• PROCEPT reported quarterly revenue of $94.5 million, up 19.3% year over year and above analyst expectations, but its adjusted loss of $0.47 per share narrowly missed estimates. Analysts’ consensus rating remains “Hold,” with an average price target of $28.
• Several law firms announced a September 22, 2026 deadline for investors to seek lead-plaintiff status in a securities class action alleging undisclosed inventory issues and sales practices; the allegations could create legal and reputational risks, though no wrongdoing has been established.

Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in shares of PROCEPT BioRobotics Corporation (NASDAQ:PRCT - Free Report) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 212,427 shares of the company's stock, valued at approximately $4,797,000. Mitsubishi UFJ Asset Management Co. Ltd. owned 0.37% of PROCEPT BioRobotics at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Prosight Management LP increased its holdings in shares of PROCEPT BioRobotics by 1,692.4% during the 4th quarter. Prosight Management LP now owns 1,380,000 shares of the company's stock worth $43,415,000 after buying an additional 1,303,009 shares during the last quarter. Alliancebernstein L.P. grew its position in PROCEPT BioRobotics by 58.6% in the third quarter. Alliancebernstein L.P. now owns 3,419,784 shares of the company's stock worth $122,052,000 after acquiring an additional 1,262,928 shares during the period. T. Rowe Price Investment Management Inc. increased its stake in PROCEPT BioRobotics by 59.4% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,271,408 shares of the company's stock worth $102,919,000 after acquiring an additional 1,218,815 shares during the last quarter. UBS Group AG raised its position in PROCEPT BioRobotics by 129.3% in the third quarter. UBS Group AG now owns 944,545 shares of the company's stock valued at $33,711,000 after purchasing an additional 532,530 shares during the period. Finally, Millennium Management LLC lifted its stake in shares of PROCEPT BioRobotics by 690.0% in the 4th quarter. Millennium Management LLC now owns 383,137 shares of the company's stock valued at $12,053,000 after purchasing an additional 448,077 shares during the last quarter. 89.46% of the stock is currently owned by institutional investors and hedge funds.

PROCEPT BioRobotics News Roundup

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Neutral Sentiment: Multiple law firms reminded investors that September 22, 2026 is the deadline to seek appointment as lead plaintiff in a class action covering purchases of PROCEPT stock from February 28, 2024, through February 25, 2026. These announcements are largely duplicative investor-solicitation notices rather than new company disclosures. Kaplan Fox class-action deadline notice
• Negative Sentiment: The lawsuits allege that PROCEPT failed to disclose inventory problems, including excess customer inventory tied to late-quarter bulk discounts, while investors focused on handpiece sales as a measure of procedure demand. The allegations claim that later revelations led to a substantial stock decline, including an approximately 18% drop referenced in one notice and a decline of more than 75% from the class-period high in another. Hagens Berman PROCEPT class-action notice
• Negative Sentiment: The litigation introduces potential legal costs, reputational risk and further scrutiny of PROCEPT’s sales practices, inventory management and underlying procedure demand. The notices do not establish wrongdoing, and no new operational update or company response was provided in the supplied articles. Kahn Swick and Foti PROCEPT securities-fraud notice

PROCEPT BioRobotics Stock Up 4.6%

Shares of PRCT opened at $21.68 on Friday. The company's 50-day simple moving average is $20.40 and its 200-day simple moving average is $24.20. The company has a debt-to-equity ratio of 0.15, a quick ratio of 5.35 and a current ratio of 6.55. PROCEPT BioRobotics Corporation has a 1 year low of $16.67 and a 1 year high of $42.43. The stock has a market capitalization of $1.24 billion, a PE ratio of -11.18 and a beta of 0.89.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last announced its earnings results on Tuesday, August 4th. The company reported ($0.47) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($0.01). The business had revenue of $94.50 million for the quarter, compared to analysts' expectations of $92.77 million. PROCEPT BioRobotics had a negative return on equity of 30.62% and a negative net margin of 32.53%.PROCEPT BioRobotics's quarterly revenue was up 19.3% on a year-over-year basis. During the same period in the previous year, the company earned ($0.35) earnings per share. Analysts forecast that PROCEPT BioRobotics Corporation will post -1.67 earnings per share for the current fiscal year.

Analysts Set New Price Targets

PRCT has been the topic of several research analyst reports. Robert W. Baird set a $20.00 price objective on shares of PROCEPT BioRobotics in a report on Wednesday, August 5th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of PROCEPT BioRobotics in a research note on Friday, July 17th. TD Cowen reduced their price target on shares of PROCEPT BioRobotics from $34.00 to $28.00 and set a "buy" rating on the stock in a research note on Wednesday, August 5th. Wall Street Zen raised shares of PROCEPT BioRobotics from a "strong sell" rating to a "sell" rating in a research note on Saturday, April 25th. Finally, Citigroup lowered shares of PROCEPT BioRobotics to a "hold" rating in a report on Thursday, July 2nd. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, ten have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $28.00.

Insider Activity at PROCEPT BioRobotics

In related news, CEO Larry L. Wood acquired 23,900 shares of the business's stock in a transaction dated Friday, August 7th. The shares were acquired at an average price of $20.85 per share, with a total value of $498,315.00. Following the completion of the transaction, the chief executive officer owned 23,900 shares of the company's stock, valued at $498,315. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders have sold a total of 1,000 shares of company stock valued at $28,480 in the last three months. Insiders own 4.00% of the company's stock.

PROCEPT BioRobotics Profile

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company's technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company's flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source